no more compounded tirzepatide Compounding pharmacies can resume making as FDA reconsiders shortage Tirzepatide $125/mo Compounded (vs $1,069
Description
The risk of bias was considered low in all the included RCTs
This peptide, which they named 'exendin-4', not only stimulated insulin secretion in the same way as GLP-1 but also had the advantage that it remained active for more than two hours after subcutaneous injection
The app requires no lab work, medical screening, or prescription
People with specific historiessuch as medullary thyroid carcinoma, MEN 2, certain pancreatic or gallbladder diseasesmay not be appropriate candidates
